title: Meta-analysis of the clinical value of oxymatrine on sustained virological response in chronic hepatitis B.
abstract: Introduction. Oxymatrine (OMTR) is widely used for the treatment of chronic hepatitis B (CHB) in China. Several recent reports revealed that OMTR together with interferon yielded a higher sustained virological response (SVR) than interferon alone.
  
  
  OBJECTIVE
  To elucidate this topic using meta-analysis of data from published randomized controlled trials (RCTs).
  
  
  METHODS
  The Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, China National Knowledge Infrastructure, Wanfang Database and China Biomedical Database were searched to identify RCTs that evaluated SVR to interferón therapies and interferon plus OMTR therapies in CHB patients.
  
  
  RESULTS
  The literature search yielded 238 studies, and 11 RCTs comprising 968 patients matched the selection criteria. Overall, SVR was significantly higher in patients treated with interferon plus OMTR than in patients treated with interferon alone (SVR: 60.7 vs. 39.8%; relative risk: 1.56; 95% confidence interval: 1.37-1.77; p < 0.05). Combined therapy of interferon plus OMTR were also superior to interferon therapies alone in achieving the endof-treatment viral response, alaninetransaminase normalization, HBeAg loss, and HBeAg seroconversion.
  
  
  CONCLUSIONS
  Combined therapy of interferon plus OMTR may yield a higher SVR than interferon therapies. The exact outcome needs to perform rigorously designed, multicenter, and large randomized controlled trials.
authors.affiliation: Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
authors.forename: Min
authors.initials: M
authors.lastname: He
authors.affiliation: Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
authors.forename: Mengmeng
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
authors.forename: Wenwen
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Jiang
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D004359:Drug Therapy, Combination; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011807:Quinolizines / Q000627:therapeutic use*; D000072230:Sustained Virologic Response; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D007372:Interferons; D011092:Polyethylene Glycols; D011807:Quinolizines; C037573:oxymatrine; D000093842:Matrines